Most tumours have an aberrantly activated lipid metabolism 1,2 that enables them to synthesize, elongate and desaturate fatty acids to support proliferation. However, only particular subsets of cancer cells are sensitive to approaches that target fatty acid metabolism and, in particular, fatty acid desaturation 3 . This suggests that many cancer cells contain an unexplored plasticity in their fatty acid metabolism. Here we show that some cancer cells can exploit an alternative fatty acid desaturation pathway. We identify various cancer cell lines, mouse hepatocellular carcinomas, and primary human liver and lung carcinomas that desaturate palmitate to the unusual fatty acid sapienate to support membrane biosynthesis during proliferation. Accordingly, we found that sapienate biosynthesis enables cancer cells to bypass the known fatty acid desaturation pathway that is dependent on stearoyl-CoA desaturase. Thus, only by targeting both desaturation pathways is the in vitro and in vivo proliferation of cancer cells that synthesize sapienate impaired. Our discovery explains metabolic plasticity in fatty acid desaturation and constitutes an unexplored metabolic rewiring in cancers.
Most tumours have an aberrantly activated lipid metabolism 1,2 that enables them to synthesize, elongate and desaturate fatty acids to support proliferation. However, only particular subsets of cancer cells are sensitive to approaches that target fatty acid metabolism and, in particular, fatty acid desaturation 3 . This suggests that many cancer cells contain an unexplored plasticity in their fatty acid metabolism. Here we show that some cancer cells can exploit an alternative fatty acid desaturation pathway. We identify various cancer cell lines, mouse hepatocellular carcinomas, and primary human liver and lung carcinomas that desaturate palmitate to the unusual fatty acid sapienate to support membrane biosynthesis during proliferation. Accordingly, we found that sapienate biosynthesis enables cancer cells to bypass the known fatty acid desaturation pathway that is dependent on stearoyl-CoA desaturase. Thus, only by targeting both desaturation pathways is the in vitro and in vivo proliferation of cancer cells that synthesize sapienate impaired. Our discovery explains metabolic plasticity in fatty acid desaturation and constitutes an unexplored metabolic rewiring in cancers.
Cancer cells display differential usage of stearoyl-CoA desaturase (SCD)-dependent fatty acid desaturation 3 (Extended Data Fig. 1a ). To illuminate this plasticity, we treated liver (HUH7), lung (A549 and H460), prostate (DU145) and breast (MDA-MB-468 and T47D) cancer cells with the SCD inhibitor Merck Frosst compound 3j 4 , in conditions of low extracellular fatty acid availability. We observed that these different cell lines exhibited a broad sensitivity profile toward SCD inhibition (Fig. 1a ). On the basis of this proliferation response, we classified these cancer cells as SCD-dependent (inhibition of proliferation, or cell death), partially SCD-dependent (less than 50% proliferation) or SCD-independent (more than 50% proliferation). Next, we excluded the possibility that the differential dependency of cancer cells on SCD activity was a result of their individual growth rate, fatty acid synthesis rate or the degree to which Merck Frosst compound 3j inhibited SCD (Extended Data Fig. 1b-g) . We concluded on the basis of these results that some cancer cells are SCD-independent, which cannot be explained by their known fatty acid metabolism. Consequently, we hypothesized that SCD-independent and partially SCD-dependent cancer cells exploit an alternative desaturation pathway. We reasoned that the presence of such an alternative pathway must result in the synthesis of unusual monounsaturated fatty acids, and therefore measured saturated and monounsaturated C12 to C18 fatty acids. In general, the different cancer cells presented a wide range of total fatty acid abundance, which did not correlate with SCD independence (Extended Data Fig. 1h, Supplementary Table 1a, b ). Yet, we discovered an elevated abundance of the unusual fatty acid sapienate (cis-6-C16:1) in SCD-independent and partially SCD-dependent cancer cells that increased upon SCD inhibition (Fig. 1b , Extended Data Fig. 2a , Supplementary Table 1a , b).
Sapienate is a major component of human sebum and is to date considered a specific marker of sebocyte metabolism in the sebaceous glands 5, 6 . Because sebocytes produce sapienate from palmitate, we determined the desaturation activity from palmitate to sapienate by assessing the sapienate-to-palmitate ratio and sapienate biosynthesis. Both measures increased upon SCD inhibition in the cell lines we tested, with the exception of SCD-dependent T47D cells (Extended Data Fig. 2b, c) . Moreover, the sapienate-to-palmitate ratio correlated with SCD independence, and was higher in SCD-independent (HUH7) and partially SCD-dependent (DU145) cancer cells compared to non-transformed cells of the same tissue origin ( Fig. 1c , Extended Data Fig. 2d ). Subsequently, we determined the desaturation activity of palmitate to sapienate in the HUH7 tumour xenografts upon SCD inhibition. Consistent with our in vitro data, we found that SCD inhibition did not significantly alter final tumour weight, but did increase the desaturation activity to sapienate (Fig. 1d , Extended Data Fig. 2e ). Accordingly, we observed that diethylnitrosamine-and genetically induced mouse hepatocellular carcinoma (HCC) exhibited a significantly elevated desaturation activity to sapienate, as compared to normal liver (Fig. 1e, f) . These data collectively show that cancer cells, and in particular HCC, can produce sapienate both in vitro and in vivo.
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In sebocytes, sapienate is produced by fatty acid desaturase 2 (FADS2) 5 (Extended Data Fig. 1a ). Therefore, we investigated whether cancer cells exploit FADS2 to synthesize sapienate. We found that FADS2 gene expression was increased in SCD-independent and partially SCD-dependent cancer cells, compared to SCD-dependent cells, and in liver and prostate cancer cells upon SCD inhibition (Extended Data Fig. 2f , g). Consistently, FADS2 protein expression correlated with SCD independence and desaturation activity to sapienate in cancer cells ( Fig. 1g, h) . Moreover, FADS2 protein and gene expression was elevated in HUH7 and DU145 cancer cells compared to corresponding non-transformed cells (Extended Data Fig. 2h ). Similarly, FADS2 gene expression was increased in matched pairs of cancer versus adjacent non-cancerous tissue of HCC (3 out of 4) and non-small-cell lung cancer (8 out of 10) from human patients ( Fig. 1i, j) . These data suggest an involvement of FADS2 in sapienate biosynthesis. Accordingly, FADS2 silencing resulted in a decreased desaturation activity to sapienate in vitro and in vivo ( Fig. 1k , l, Extended Data Fig. 2i ). These findings demonstrate that some cancer cells exploit FADS2 to produce sapienate.
Next, we investigated whether sapienate biosynthesis causes SCD independence. Sapienate supplementation or FADS2 overexpression in SCD-dependent MDA-MB-468 cells restored proliferation upon SCD inhibition and thus resulted in SCD independence ( Fig. 2a , b, Extended Data Fig. 3a ). Moreover, FADS2 silencing combined with SCD inhibition caused the inhibition of proliferation in HUH7 cells and cell death in A549 cells ( Fig. 2c, d) , whereas sole FADS2 knockdown seemed to increase proliferation in HUH7 cells. These findings indicate that some cancer cells might rely on the metabolic plasticity provided through simultaneous SCD and FADS2 desaturation activity at the expense of maximized proliferation-a phenomenon that has previously been described 7 . Subsequently, we assessed dual inhibition of SCD-and FADS2-dependent desaturation in HUH7 orthotopic liver xenografts. We found that only dual inhibition of SCD and FADS2 resulted in a significantly smaller tumour area compared to control tumours ( Fig. 2e, f ). Unlike the in vitro results, no full inhibition of tumour growth was achieved in vivo; this was probably due to the lower in vivo knockdown efficiency and a partial compensation through extracellular sapienate uptake (Extended Data Fig. 3b-d ). An involvement of linoleate-a known substrate of FADS2 in polydesaturation-in the observed SCD independence was excluded (Extended Data Fig. 3e -h). Taken together, these data demonstrate that dual activity of SCD-and FADS2-dependent desaturation can provide metabolic plasticity that supports proliferation, which can be impaired in vitro and in vivo by the combined inhibition of both pathways.
An important fate of fatty acids is membrane synthesis, for which fatty acids are often elongated. Accordingly, we observed carbons of sapienate in its elongation product cis-8-octadecenoate (cis-8-C18:1; Extended Data Fig. 4 ). Consistent with sapienate elongation, the abundance of cis-8-octadecenoate was higher in SCD-independent cells than in SCD-dependent cells, increased in HUH7 and A549 cells upon sapienate supplementation or SCD inhibition, and decreased upon FADS2 silencing ( Fig. 3a Fig. 2b ). Trend line (dashed line); 95% confidence intervals (dotted lines). n = 3. i, j, FADS2 gene expression in paired samples of human HCC (n = 4) and non-small-cell lung adenocarcinoma (n = 10) versus normal adjacent tissue. k, Desaturation activity to sapienate in HUH7 and A549 cells with a non-targeting short hairpin RNA (shRNA) or one of two shRNAs targeting FADS2 (shFADS2-1 and shFADS2-2) (n = 3). One-way ANOVA with Dunnett's multiple comparisons. l, Sapienate-to-palmitate ratio in normal adjacent liver and HUH7 orthotopic liver tumours with non-targeting shRNA or an shRNA targeting FADS2 (shFADS2-2) (n = 5). Two-way ANOVA with Data Fig. 5d -f). We then determined whether sapienate is used for membrane synthesis. FADS2 silencing altered the overall composition of membrane-bound phospholipids, decreased the fraction of phospholipids built from sapienate and increased phospholipids built from the SCD product palmitoleate in HUH7 and A549 cells ( Fig. 3c , Extended Data Fig. 6a -e, Supplementary Table 1e ). The opposite change occurred upon SCD inhibition ( Fig. 3d, e ). Functionally, these changes in membrane composition resulted in a trend towards decreased membrane fluidity and increased resistance to lipid peroxidation in FADS2 knockdown cells (Extended Data Fig. 6f , g). Thus, these data show that some cancer cell lines elongate sapienate and use it for membrane biosynthesis.
Finally, we asked whether sapienate metabolism also occurs in primary human cancers. We measured the ratio of sapienate to palmitate in cancer and normal lung and liver tissue, as well as in blood plasma from human subjects. Blood plasma was obtained from healthy volunteers or patients with cancer, and normal lung and liver was obtained from adjacent non-cancerous tissue from patients with cancer and non-transplanted donor organs, respectively. In addition, we determined the palmitoleate-to-palmitate ratio in the same tissues and blood plasma samples as a readout of the SCD-dependent fatty acid desaturation pathway. We found that in cancer tissue, but not in normal tissue, the sapienate-to-palmitate ratio was significantly increased compared to the ratio in blood plasma ( Fig. 4a, b ). Accordingly, the sapienate-to-palmitate ratio was higher in cancer tissue than in normal tissue ( Fig. 4a, b ). The increase in the sapienate-to-palmitate ratio was more pronounced than the corresponding change in the palmitoleate-to-palmitate ratio when comparing cancer and normal tissue ( Fig. 4a, b ). This suggests a specific increase in sapienate biosynthesis in these cancers, rather than a general increase in the synthesis of monounsaturated fatty acids. Taken together, these data provide evidence that sapienate metabolism occurs in vivo in primary lung and liver carcinomas from human patients.
The well-characterized SCD-dependent fatty acid desaturation pathway has previously been considered to be the only source of de novo-generated monounsaturated fatty acids in cancer cells 8 . Here we show that cancer cells can rewire their fatty acid metabolism and desaturate palmitate to the unusual fatty acid sapienate ( Fig. 4c ). Particularly, Letter reSeArCH we find evidence for sapienate metabolism in human lung and liver carcinoma. This finding can explain metabolic plasticity, and demonstrates heterogeneity in the fatty acid desaturation metabolism of cancer cells. Although we find that sapienate and cis-8-octadecenoate can support membrane synthesis, it is tempting to speculate that sapienate and its elongation products affect the known fatty acid and lipid signalling networks of cancer cells [9] [10] [11] . Consequently, this could provide cancer cells with a hitherto unexplored possibility to deregulate signalling networks, opening new opportunities to understand and target them. In conclusion, our discovery increases the current understanding of fatty acid metabolism in cancers and suggests sapienate biosynthesis as an alternative source of monounsaturated fatty acids.
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Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/s41586-019-0904-1. Knockdown and overexpression strategies. FADS2 knockdown cell lines were generated using the shRNA-expressing lentiviral pLKO1-puro vector with a puromycin selection cassette (Plasmid 8453; Addgene). Clone identities for shRNAs were as follows: shFADS2-1 (TRCN0000064755; sequence: CCGGCCACGGCAAG-AACTCAAAGATCTCGAGATCTTTGAGTTCTTGCC GTGGTTTTTG) and shFADS2-2 (TRCN0000064757; sequence: CCGGC CAC CTGTCTGTCTACAGAAACTCGAGTTTCTGTAGA-CAGACAGGTGGT TT TTG) (Sigma-Aldrich). A scrambled shRNA (TRC1 sequence: AACAAGATG AAGAGCACCAA) was used as a negative control for FADS2 knockdown cells. FADS2 overexpression cell lines were generated using the pLVX-IRES-Hyg vector with a hygromycin selection cassette (Clontech Laboratories). An empty pLVX-IRES-Hyg vector served as a negative control for FADS2 overexpression. Lentiviruses were produced by transfection of HEK293T cells. Transduction of cells was performed overnight and the medium was replaced the next day. Polyclonal cells were selected for 1-2 weeks with puromycin (in the case of knockdown cells) or with hygromycin (in the case of overexpression), before experiments were performed. All knockdown and overexpression cell lines were validated by quantitative real-time PCR (qRT-PCR) and protein analysis (Extended Data Figs. 2i, 3a) . Primers for FADS2 were designed to amplify a cDNA segment in the sequence as follows: forward primer 5′-gaccacggcaagaactcaaag-3′ and reverse primer 5′-gagggt aggaatccagccatt-3′. For SCD1, the forward and reverse primers used were 5′-tctctgctacacttgggagc-3′ and 5′-gagctttgtaagagcggtgg-3′, respectively. Relative gene transcript levels were compared to the control gene RPL19, with 5′-attggtctcatt ggggtctaac-3′ and 5′-agtatgctcaggcttcagaaga-3′ as forward and reverse primer, respectively. forward primer 5′-gaccacggcaagaactcaaag-3′ and reverse primer 5′-gagggtaggaatcc agccatt-3′; RPLP0 forward primer 5′-gaaactctgcattctcgcttc-3′ and reverse primer 5′-ggtgtaatccgtctccacag-3′. Human non-small-cell lung cancer and adjacent normal lung samples were retrieved from patients enrolled in an IRB-approved protocol, after obtaining informed consent (ClinicalTrials.gov identifier, NCT02095808). On the basis of pre-operative imaging and gross inspection at resection, viable fragments of tumour and lung were sampled. RNA isolation was carried out using the Trizol reagent (Thermo Fisher Scientific) and FastPrep-24 (MPbio). cDNA synthesis was performed using 1 μg of RNA with the qScript cDNA Synthesis Kit (QuantaBio). Analysis of FADS2 gene expression was performed by qRT-PCR using Platinum SYBR Green qPCR SuperMix-UDG (Thermo Fisher Scientific) on a Viia7 Real Time PCR system (Applied Biosystems, Life Technologies). Amplification was performed at 95 °C for 10 min, followed by 40 cycles of 15 s at 95 °C and 1 min at 60 °C. Primers for FADS2 were designed to amplify a cDNA segment in the sequence as follows: forward primer 5′-gaccacggcaagaactcaaag-3′ and reverse primer 5′-gagggtaggaatccagccatt-3′. Relative gene transcript levels were compared to the control gene RPL19, with 5′-attggtctcattggggtctaac-3′ and 5′-agtatgctcaggcttcagaaga-3′ as forward and reverse primer, respectively. Samples were assayed in triplicates. Growth and labelling experiments. Cancer cells were seeded in the wells of 12-well plates (Corning) at either 7 × 10 4 cells per well (HUH7, A549, H460 and DU145), 1.5 × 10 5 cells per well (MDA-MB-468) or 2 × 10 5 cells per well (T47D) in low FBS DMEM (1.5 ml per well) and grown in a humidified environment at 37 °C with 5% CO 2 . For HUH7, 1% FBS was considered low FBS DMEM; for all other cell lines, 0.5% FBS was used. Low FBS (0.5-1%) DMEM contains a total of 4.31-8.62 μM fatty acids, with palmitate, oleate and stearate being the most abundant fatty acids (Extended Data Fig. 7a ). After 24 h, the medium was aspirated, cells were washed with DPBS and low FBS DMEM (4.5 g per l glucose for growth experiments or 4.5 g per l 13 C 6 -glucose for labelling experiments, including fatty acid synthesis assessment), supplemented with 0.1% DMSO (control) or Merck Frosst compound 3j (either at 0.5 nM, 1 nM or 2 nM concentration dissolved in DMSO) added to the wells (1.5 ml per well). Treatment was carried out for 72 h, during which cells were grown in a humidified environment at 37 °C with 5% CO 2 .
For growth experiments, cells were counted before treatment (initial count) and 72 h after treatment (final count) using a Moxi Z Mini Automated Cell Counter (Orflo Technologies) or a Countess II Automated Cell Counter (Thermo Fisher Scientific) following trypsinization. Cell number change was calculated by subtracting the initial count from the final count, and was subsequently normalized to the control condition, unless stated otherwise. For labelling experiments, cells were washed with saline solution after treatment and metabolism was quenched by flash-freezing the plates in liquid nitrogen. Plates were stored at -80 °C until metabolite extraction. All experiments were performed in triplicates. Key experiments were confirmed in medium with glucose and amino acid concentrations similar to blood (BLM) 12, 13 in low FBS (Extended Data Fig. 7b-h) .
For rescue experiments, cells were seeded and grown as described above. After 24 h, the medium was replaced by medium containing 0.1% DMSO (control) or Merck Frosst compound 3j (0.5 nM, 1 nM or 2 nM), supplemented with either 1% ethanol (control) or 20 μM palmitoleate (cis-9-16:1), sapienate (cis-6-16:1), oleate (cis-9-18:1) or cis-8-octadecenoate (cis-8-C18:1) dissolved in ethanol. Cells were counted before treatment and 72 h after treatment using a Moxi Z Mini Automated Cell Counter (Orflo Technologies) or a Countess II Automated Cell Counter (Thermo Fisher Scientific) following trypsinization, and relative cell number changes were calculated as described above. All experiments were performed in triplicates. Changes in intracellular fatty acid abundance upon supplementation were confirmed by mass spectrometry (Supplementary Table 1c, d) .
Primary hepatocytes of one donor were obtained from the Hepatocytes and Liver Stem Cell Bank, Cliniques Universitaires St Luc. Cells were thawed using the Corning Gentest High Viability CryoHepatocyte Recovery Kit (Corning). Cells were then plated on collagen-I-coated 6-well plates at a density of 1.4 × 10 6 cells per well, and left to attach for 8 h in Corning Plating Medium (Corning). Reverse labelling experiments. HUH7 and A549 cells were seeded at 1 × 10 6 cells per flask in T75 flasks in low FBS (1% FBS, HUH7) or 10% FBS (A549) DMEM and grown as described above. After 24 h, the medium was aspirated, cells were washed with DPBS and 1% (HUH7) or 10% (A549) dialysed FBS DMEM (4.5 g per l 13 C 6 -glucose) was added to the cells. Cells were cultured for 1 week (medium was replaced every 3 days) to fully label all cellular metabolites. Next, cells were trypsinized, washed and seeded in the wells of a 12-well plate at 7 × 10 4 cells per well in low FBS DMEM containing 4.5 g per l 13 C 6 -glucose (1% FBS for HUH7 and 0.5% FBS for A549). After 24 h, the medium was aspirated, cells were washed with DPBS and low FBS DMEM containing 4.5 g per l 13 C 6 -glucose (1% FBS for HUH7 and 0.5% FBS for A549) supplemented with either 1% ethanol (control) or 20 μM 12 C-sapienate (cis-6-16:1) dissolved in ethanol was added to the cells (1.5 ml per well). Treatment was carried out for 72 h. After treatment, cells were washed with saline solution and metabolism was quenched by flash-freezing the plates in liquid Letter reSeArCH nitrogen. Plates were stored at -80 °C until metabolite extraction. All experiments were performed in triplicates.
If fully labelled cells use 12 C-sapienate, a decrease in the 13 C enrichment will be observed in the metabolites into which sapienate is incorporated, such as cis-8octadecenoate. Because our gas chromatography-mass spectrometry (GC-MS) setup does not allow for separation of cis-8-and cis-9-octadecenoate, and our gas chromatography-flame ionization detector (GC-FID) setup does not allow for assessment of 13 C enrichment, we opted to assess the 13 C enrichment in the pool of octadecenoate (consisting of cis-8-and cis-9-octadecenoate) via GC-MS. Note that only cis-8-octadecenoate, and not cis-9-octadecenoate, can result from sapienate metabolism. Therefore, a decrease in 13 C enrichment in the octadecenoate pool indicates the incorporation of 12 C-sapienate into cis-8-octadecenoate. Metabolite extraction and metabolite measurement. Metabolite extractions were performed using previously described methods 14, 15 . In brief, for 12-well cell culture plates containing 1-5 × 10 5 cells per well, the medium was aspirated, cells were washed with blood bank saline, and cell metabolism was quenched by flash-freezing the plates in liquid nitrogen. Next, 400 μl of -20 °C cold 65% methanol was added to the wells, cells were scraped with a pipette tip and suspensions were transferred to Eppendorf tubes. Next, 250 μl of -20 °C cold chloroform was added and samples were vortexed at 4 °C for 10 min to extract metabolites. Phase separation was achieved by centrifugation at 4 °C for 10 min, after which the chloroform phase (containing the total fatty acid content) was separated and dried by vacuum centrifugation. For tissue samples, tissues were weighed (5-10 mg) and pulverized (Cryomill, Retsch) under liquid nitrogen conditions. For plasma samples, 10 μl (mouse) or 50 μl (human) of cold plasma was transferred to an Eppendorf tube. Next, 800 μl of -20 °C cold 65% methanol was added to the samples, followed by 500 μl of -20 °C cold chloroform. Samples were then handled as described above. Dried fatty acid samples were immediately processed to fatty acid methyl esters as described below, thereby avoiding degradation.
Total fatty acid samples were esterified with 500 μl 2% sulfuric acid in methanol for 180 min at 60 °C or overnight at 50 °C and extracted by addition of 600 μl hexane and 100 μl saturated aqueous NaCl. Samples were centrifuged for 5 min and the hexane phase was separated and dried by vacuum centrifugation. Samples were resuspended in hexane, after which isotopologue distributions of fatty acids were measured with a 7890A GC system (Agilent Technologies) combined with a 5975C or a 7000 inert MSD system (Agilent Technologies). One microlitre of each sample was injected in splitless (5975C) or 5:1 split (7000) mode with an inlet temperature of 270 °C onto a DB35MS column (Agilent Technologies). Helium was used as a carrier gas with a flowrate of 1 ml per min. The oven was held at 80 °C for 1 min and ramped with 5 °C per min to 300 °C. The mass spectrometry system was operated under electron impact ionization at 70 eV and a mass range of 100-650 amu was scanned. Evidence for separation of cis-6-C16:1 and cis-9-C16:1 is presented in Extended Data Fig. 8a . Isotopologue distributions were extracted from the raw chromatograms using an in-house MATLAB script. Correction for naturally occurring isotopologues was achieved using Isocor software. Palmitate, palmitoleate and sapienate synthesis were calculated on the basis of isotopologue distributions of the according fatty acid, using isotopomer spectral analysis 16 and an in-house MATLAB script. For determination of relative metabolite abundances, the total ion counts were normalized to an internal standard (pentadecanoate or heptadecanoate) and the cell number or protein content for cell extracts. For tissue extracts, the total ion counts were normalized to the internal standard (pentadecanoate or heptadecanoate) and tissue weight. The desaturation activity from palmitate to sapienate or palmitoleate was calculated by dividing the normalized total ion count of sapienate or palmitoleate by the normalized total ion count of palmitate.
cis-8-Octadecenoate abundances were measured with a GC-FID system (TRACE GC ULTRA, Thermo Fisher Scientific). One microlitre of each sample was injected onto a SLB-IL111 capillary column (100 m × 0.25 mm ID, 0.20-μm thickness, Supelco) with an inlet temperature of 250 °C. Helium was used as a carrier gas at 1.2 ml per min and the oven temperature was maintained isothermally at 140 °C. cis-C18:1 isomers (∆8,9,11) were synthesized as previously described 17 , processed to fatty acid methyl esters, and used for validation of the separation of cis-C18:1 isomers and confirmation of the retention times of respective cis-C18:1 fatty acid methyl esters. Evidence for separation of cis-8-C18:1 and cis-9-C18:1 is presented in Extended Data Fig. 8b . For determination of relative cis-8octadecenoate abundances, the total ion counts were normalized to the internal standard (pentadecanoate or heptadecanoate). For cell extracts, total ion counts were further normalized to the protein content or to the total fatty acid abundance. Total ion counts in tissue samples were further normalized to tissue weight. FADS2 protein analysis. Human cell pellets (1-4 × 10 7 cells per pellet) in triplicate were lysed in a urea lysis buffer containing 8 M urea and 20 mM HEPES pH 8.0. Cell pellets were homogenized by sonication on a Diagenode Bioruptor Plus instrument using the following settings: high intensity power output, 10 cycles of 30-s on/30-s off pulses, 4 °C water bath. The protein concentration in each lysate was measured by Bradford (Bio-Rad Laboratories) and aliquots containing 100 μg of protein were used for further analysis. Proteins were reduced by addition of DTT to a concentration of 5 mM and incubation for 30 min at 55 °C. Next, proteins were alkylated by addition of iodoacetamide to a concentration of 10 mM for 15 min at room temperature in the dark. Samples were diluted with 20 mM HEPES pH 8.0 to a urea concentration of 4 M and proteins were digested with 1 μg lysyl endopeptidase (Wako Chemicals) (1/100, w/w) for 4 h at 37 °C. Samples were further diluted with 20 mM HEPES pH 8.0 to a final urea concentration of 2 M and proteins were digested with 1 μg trypsin (Promega) (1/100, w/w) overnight at 37 °C. The resulting peptide mixture was purified using OMIX C18 pipette tips (Agilent Technologies) or SampliQ SPE C18 cartridges (Agilent Technologies) and 100 μg of peptides of each sample were dried completely by vacuum drying and stored at -20 °C until further use.
Peptides were re-suspended in loading solvent (0.1% TFA in water/acetonitrile, 98/2 (v/v)) and 3 μg was injected for liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis on an Ultimate 3000 RSLC nano LC (Thermo Fisher Scientific) in-line-coupled to a Q Exactive HF mass spectrometer (Thermo Fisher Scientific). The peptides were first loaded on a trapping column (made in-house, 100-μm internal diameter (I.D.) × 20 mm, 5-μm beads C18 Reprosil-HD, Dr. Maisch) and after flushing from the trapping column, peptides were separated on an analytical column in the needle (made in-house, 75 μm I.D. × 400 mm, 1.9-μm beads C18 Reprosil-HD, Dr. Maisch) using a nonlinear 150 min gradient of 2 to 56% solvent B (0.1% formic acid in water/acetonitrile, 20/80 (v/v)) at a constant flow rate of 250 nl per min and at a constant temperature of 50 °C (CoControl 3.3.05, Sonation). Following a 10-min wash reaching 99% solvent B, the column was re-equilibrated with solvent A (0.1% formic acid in water).
The mass spectrometer was operated in data-dependent, positive ionization mode, automatically switching between mass spectra and tandem mass spectra acquisition for the 16 most abundant peaks in a given mass spectrum. The source voltage was set to 2.5 kV and the capillary temperature was 250 °C. One MS1 scan (m/z 375-1,500, AGC target 3 × 10 6 ions, maximum ion injection time of 60 ms), acquired at a resolution of 60,000 (at 200 m/z) was followed by up to 16 tandem mass spectrometry scans, acquired at a resolution of 15,000 (at 200 m/z) of the most intense ions fulfilling predefined selection criteria: AGC target 1 × 10 5 ions, maximum ion injection time of 80 ms, isolation window of 1.5 m/z, fixed first mass of 145 m/z, spectrum data type: centroid, under fill ratio 2%, intensity threshold 1.3 × 10 4 , exclusion of unassigned and singly charged precursors, peptide match preferred, exclude isotopes on, dynamic exclusion time of 12 s. The normalized collision energy was set to 28% and the polydimethylcyclosiloxane background ion at 445.12003 Da was used for internal calibration (lock mass).
Data analysis was performed by MaxQuant (version 1.6.1.0) using the Andromeda search engine with default search settings, including a false discovery rate set at 1% on both the peptide and protein level. Spectra were searched against the human proteins in the Swiss-Prot database (database release version of December 2017, containing 20,243 human protein sequences; downloaded from www.uniprot.org). The mass tolerance for precursor and fragment ions was set to 4.5 and 20 p.p.m., respectively, during the main search. Enzyme specificity was set as C-terminal to arginine and lysine (trypsin), also allowing cleavage at arginineproline or lysine-proline bonds with a maximum of two missed cleavages. Carbamidomethylation of cysteine residues was set as a fixed modification and variable modifications were set to oxidation of methionine residues (to sulfoxides) and acetylation of protein N termini. Proteins were quantified by the MaxLFQ algorithm integrated in the MaxQuant software. Only proteins with at least one unique or razor peptide were retained for identification, and a minimum ratio count of two unique peptides was required for quantification. The obtained labelfree quantification intensity values of FADS2 were used to quantify the protein, and to compare levels of FADS2 between different samples. Analysis of phospholipid-bound sapienate and palmitoleate. HUH7 cells carrying a non-targeting shRNA or a shRNA targeting FADS2 (shFADS2-2) were seeded in T75 flasks, allowed to attach for 24 h and subsequently grown for 72 h in 1% FBS DMEM. Cells were trypsinized, washed with blood bank saline and re-suspended in TAG lysis buffer (1% IGEPAL CA-630 (Nonidet P-40), 50 mM Trizma hydrochloride and 150 mM sodium chloride). Lipids were extracted from cell lysate according to the Folch method 18 . An internal standard containing a known concentration of 1,2-diheptanoyl-sn-glycero-3-phosphocholine (17:0) was added to samples before extraction to allow the quantification of total phospholipids. Lipid fractions were separated by thin-layer chromatography and fatty acid methyl esters were prepared as previously described 19, 20 . Separation and detection of total phospholipid fatty acid methyl esters was achieved using a 6890N Network GC System (Agilent Technologies) with flame ionization detection. Fatty acid methyl esters were identified by their retention times compared to a standard containing 31 known fatty acids and quantified in micromoles from the peak area based on their molecular mass. The micromole quantities were then totalled and each fatty acid was expressed as a percentage of this value Letter reSeArCH (molar percentage (mol%)), or as micrograms of fatty acids normalized to cellular protein amount. Analysis of phospholipid species. HUH7 and A549 cells carrying a non-targeting shRNA or one of two shRNAs targeting FADS2 (shFADS2-1 or shFADS2-2) were seeded in T75 flasks, allowed to attach for 24 h and subsequently grown for 72 h in low FBS DMEM (1% FBS for HUH7; 0.5% FBS for A549). Cells were trypsinized, washed three times with cold DPBS and cell pellets were re-suspended in 0.8 ml DPBS. Lipid extraction and multiple reaction monitoring (MRM)-based phospholipid (semi)quantification analysis was performed as previously described 21 . In brief, 0.7 ml of homogenized cells were mixed with 0.9 ml MeOH:HCl (1 M) (8:1), 0.8 ml CHCl 3 and 200 μg per ml of the antioxidant 2,6-di-tert-butyl-4-methylphenol (Sigma). The organic fractions were evaporated under vacuum using a Savant Speedvac spd111v (Thermo Fisher Scientific) at room temperature and the remaining lipid pellet was stored at -20 °C under argon. Before mass spectrometry analysis, lipid pellets were reconstituted in running solution (CH 3 OH:CHCl 3 :NH 4 OH; 90:10:1.25; v/v/v). The lipid standards phosphatidylcholine (PC)25:0, PC43:6, sphingomyelin (SM)30:1, phosphatidylethanolamine (PE)25:0, PE43:6, phosphatidylinositol (PI)25:0, PI31:1, PI43:6, phosphatidylserine (PS)25:0, PS31:1 and PS37:4 (Avanti Polar Lipids) were added based on the amount of DNA of the original sample. Phospholipids were analysed by electrospray ionization tandem mass spectrometry (ESI-MS/MS) on a hybrid quadrupole linear ion trap mass spectrometer (4000 QTRAP system, AB SCIEX) equipped with a TriVersa NanoMate robotic nanosource (Advion Biosciences) for automated sample injection and spraying as previously described 22 . Phospholipid profiling was executed by (positive or negative) precursor ion or neutral loss scanning at a collision energy of 50 eV or 45 eV, 35 eV, −35 eV and −60 eV for precursor 184 (SM or PC), neutral loss 141 (PE), neutral loss 87 (PS) and precursor 241 (PI), respectively. Phospholipid quantification was performed by MRM, the transitions being based on the neutral losses or the typical product ions as described above. Typically, a 3-min period of signal averaging was used for each spectrum. The data were corrected for carbon isotope effects and chain length, and analysed using in-house-developed software (RALP). As a background, the intensities of species detected in the 'internal standards only' spectra were considered after being divided by the ion suppression factor of each sample. The ion suppression factor was calculated for each sample separately by dividing the intensity of the standards in the 'internal standards only' spectrum by the intensity of the standards in the sample spectrum. Only the phospholipid species displaying an intensity of at least 5 times the blank value were taken into account. To quantify the total amount of phospholipids in a phospholipid class, the abundances of individually measured species within the phospholipid class were totalled. Data were normalized on the basis of DNA amount. MRM-based analysis of the C16:1-containing phospholipids was based a previous method 23 . Analysis of lipid peroxidation sensitivity. HUH7 control and FADS2 knockdown cells (3 × 10 7 cells each) were seeded in 15-cm Petri dishes in 1% FBS DMEM. After 24 h, cells were treated with control or 5 μM RSL3 (the latter inhibits glutathione peroxidase 4 and induces lipid peroxidation). Lipid peroxidation was quantified using the MDA assay kit (Sigma) according to manufacturer's instructions with some exceptions. In brief, 3 × 10 7 cells were collected in BHT-supplemented PBS. TBA-acetic acid solution was buffered to pH 3.5. Plates were read using an EnSpire Multimode Plate Reader (PerkinElmer). Signal was normalized to total amount of sample DNA. Analysis of membrane fluidity. HUH7 and A549 control and FADS2 knockdown cells were grown on glass coverslips (n = 4) in low FBS DMEM (1% FBS for HUH7; 0.5% FBS for A549) for 3 days and subsequently fixed for 15-30 min in 4% PFA at room temperature. For lipid phase analysis, cells were stained with di-4-ANEP-PDHQ (Thermo Fisher Scientific) according to the manufacturer's specifications. For imaging, a Nikon A1R confocal microscope attached to Ti eclipse outfitted with a Plan Apo VC 60× lens oil immersion lens with a numerical aperture of 1.4 was used (Nikon Instruments). The spectral detector was set to 530-590 and 590-650 nm to image the spectral shift of the dye from lipid ordered to disordered phases. Resulting images were analysed with NIS software (Nikon Instruments), thereby segmenting the cells in the images and calculating the ordered-todisordered ratio 24 . The higher the ordered-to-disordered ratio, the more saturated lipids are present in the membrane. Ten fields of view were imaged per coverslip. Mouse models. All mouse experiments were approved by the local authorities in compliance with all relevant ethical regulations (including, but not limited to, tumour size). For injection models, mice were randomized before injection of cancer cells. All samples were analysed blinded. Sample size was determined using power calculations with β = 0.8 and P < 0.05 based on preliminary data and in compliance with the 3R system (replacement, reduction, refinement). Subcutaneous HUH7 xenograft model. Mice were fed ad libitum a CRM (E) expanded low-fat diet (Special Diets Services 801730) one week before the start of the experiments until they were killed. HUH7 cells (1 × 10 6 ) were subcutaneously injected in 50% Matrigel, (BD Biosciences), 50% cell culture medium without FCS into 8-9-week old female immunocompromised NMRI nu/nu mice (Taconic M&B A/S). Tumours were allowed to grow up to a mean tumour size of 30 mm 2 (length × width), before mice were allocated to treatment and control group by stratified randomization based on their primary tumour size (8 mice per group). Tumour-bearing mice were either treated with vehicle (10% v/v ethanol, 40% v/v solutol) alone or with 1.5 mg per kg SCD inhibitor Merck Frosst compound 3j for six consecutive days twice daily p.o. After the last treatment, mice were euthanized and tumours were collected and snap-frozen for further analyses. Humane endpoints were determined as a tumour size of 225 mm 2 . Additionally, the following symptoms were monitored and upon detection of one of the symptoms the mouse was euthanized: ulcerated tumours, loss of 20% body weight, self-mutilation, constant circling, constant curved posture, blood attachment at body openings, bloody diarrhoea, abnormal breathing, constant eye and nasal discharge, apathic, constantly cramps, constant tremble, crouching posture and self-isolation. All mouse experiments were conducted in accordance with the European Union directives and the German animal welfare act and approved by the Landesamt für Gesundheit und Soziales (LAGeSo). DEN-induced hepatocellular carcinoma model. Male C57Bl/6N mice were obtained from the KU Leuven animal facility and injected with DEN (25 mg per kg) intraperitoneally at the age of two weeks. After 4 weeks, mice were fed with a 13 kJ% fat diet (Ssniff S8655-E220) until killed and analysed at 20, 30, 31 or 32 weeks after DEN administration. Tumour and non-tumour tissues were collected and rapidly frozen for metabolomic analysis using a liquid-nitrogen-cooled Biosqueezer (Biospec Products). Tissues were weighed (5-10 mg) and pulverized (Cryomill, Retsch) under liquid nitrogen conditions. The pulverized tissues were extracted for GC-MS analysis as described above. Humane endpoints were determined as follows: liver tumours can be detected by palpation as hard masses in otherwise soft abdominal area, or by an enlarged abdomen at later stages. In mice, a 20% increase in the normal abdomen diameter was considered as a humane endpoint. Additionally, the following symptoms were monitored and upon detection of one of the symptoms the mouse was euthanized: loss of ability to ambulate, loss of skin elasticity, laboured respiration or weight loss over 20% of initial body weight. Housing and experimental mouse procedures were approved by the Institutional Animal Care and Research Advisory Committee of the KU Leuven. Hepatocyte-specific Pten or Stk3 and Stk4 knockout hepatocellular carcinoma model. Mice were fed standard chow ad libitum throughout the procedure. C57BL/6 mice carrying Pten conditional knockout alleles were crossed with albumin (Alb)-Cretransgenic mice. Control mice were Pten loxP/loxP ;Alb-cre -, whereas the experimental mice were Pten loxP/loxP ;Alb-cre + . For hepatocyte-specific Stk3 and Stk4 deletion, mice carrying Stk3 and Stk4 conditional knockout alleles (in a mixed background of CD1, C57BL/6 and 129) were crossed with Alb-Cre-transgenic mice. Control mice were Stk3 loxP/loxP ;Stk4 loxP/loxP ;Alb-cre -, whereas the experimental mice were Stk3 loxP/loxP ;Stk4 loxP/loxP ;Alb-cre + . At necropsy (approximately 12 months for Pten and 4-6 months for Stk3 and Stk4), tumours and liver tissues were collected and snap-frozen for further analysis from male mice. Humane endpoints were determined as maximum tumour size on the basis of linear or volumetric measurements. In mice, when linear measurements are used the longest dimension of the tumour should not exceed 2.0 cm and-if multiple tumours are present-the combination of the two longest diameters may not exceed 2.0 cm. Tumour volume (TV) can also be used to evaluate tumour size using the following formula: TV = (width)2 × length/2. The maximum single tumour size or tumour burden for mice is 2,000 mm 3 . All animal procedures were approved by and carried out in accordance with the policies and regulations set forth by the Institutional Animal Care and Use Committee (IACUC) at MD Anderson Cancer Center. Hepatocyte-specific myrAKT-Nras overexpression hepatocellular carcinoma model. Wild-type FVB/N mice were obtained from Charles River and subjected to hydrodynamic injection. In brief, 10 μg of the plasmids encoding myr-AKT1 and/or Nras(V12) along with sleeping beauty transposase in a ratio of 25:1 were diluted in 2 ml saline (0.9% NaCl), filtered through a 0.22-μm filter, and injected into the lateral tail vein of 6 to 8-week-old FVB/N male mice in 5 to 7 s. After 6-9 weeks, tumours were collected and snap-frozen for further analysis. Humane endpoints were determined as follows: liver tumours can be detected by palpation as hard masses in otherwise soft abdominal area, or an enlarged abdomen at later stages. Tumours were recorded when first noticed. In mice, a 20% increase in the normal abdomen diameter was considered as a humane endpoint. Mice were housed, fed and monitored in accordance with protocols approved by the Committee for Animal Research at the University of California, San Francisco. Orthotopic HUH7 liver cancer model. Mice were fed ad libitum a CRM (E) expanded low-fat diet (Special Diets Services 801730) one week before the start of the experiments until they were killed. Next, 0.5 × 10 6 HUH7 control or shFADS2-2 cells were orthotopically injected in 100% Matrigel, (BD Biosciences) into the left liver lobe of anaesthetized (3% isoflurane, 2% oxygen) 6-week-old male immunocompromised NMRI nu/nu mice (Taconic M&B A/S). For analgesia, mice were given 5 mg per kg carprofen subcutaneously, before and after surgery and for the following 3 d.
